Cord Blood Stem Cells Information

Home > Molecular Medicine Today Information > Molecular Medicine Today News

Molecular Medicine Today News

  • Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention Monday, October 6, 2008 @ 3:51PM The Nobel Prize-winning discovery of the causal link between human papillomavirus and cervical cancer has spurred lifesaving prevention technologies -- such as HPV testing and HPV vaccines -- that are helping to eradicate cervical cancer globally.
  • Topline Results From Phase III Study Evaluating The Combination Of Avastin And Tarceva As 2nd-Line Treatment For ... Monday, October 6, 2008 @ 10:18AMGenentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
  • China milk poisoning Friday, October 3, 2008 @ 9:06AMhe current gruesome dis-covery that several dairy companies in China were using a toxic chemical additive (mela-mine) in the formulation (or reconstitution by some middlemen for retail sales) of baby milk powder/formula and other milk products like chocolates, ice-cream, flour, etc., which had caused kidney stone formation in more than 54,000 children, a few resulting in death, only underscores ...
  • Alba Therapeutics Corporation Announces Promotions Thursday, October 2, 2008 @ 3:11PM Alba Therapeutics Corporation today announced the promotions of Linda Arterburn, PhD, Francisco Leon, MD, PhD, Roberto Allen, Esquire, Mark Ginski, PhD, and Kate Huber.
  • Research Team Discovers Brain Pathway Responsible for Obesity Thursday, October 2, 2008 @ 11:28AMUniversity of Wisconsin-Madison researchers, for the first time, have found a messaging system in the brain that directly affects food intake and body weight.
  • Pradaxa - First New Oral Medication To Stop Blood Clotting In Over 50 Years Launched In Ireland Today Thursday, October 2, 2008 @ 11:19AMThe first new oral medication to stop blood  clotting  since  the  launch of warfarin in the early 1950s has been launched  today.   Pradaxa*  (dabigatran  etexilate)  is the first of a new class  of  oral  anticoagulants  - a direct thrombin inhibitor - to be made available  in  Ireland  by  Boehringer Ingelheim.
  • A New Look at Heart Disease Thursday, October 2, 2008 @ 8:52AM The latest innovative approaches to the diagnosis, therapy, and prevention of cardiovascular disease will take center stage at an upcoming international scientific symposium to be held in Boryspil, Ukraine.
  • Progenics Announces Progress and Presentations in HIV Therapy Program Thursday, October 2, 2008 @ 7:00AM TARRYTOWN, N.Y.----Progenics Pharmaceuticals, Inc. today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus infection.
  • Roche Diagnostics Extends License for Universal ProbeLibrary (UPL) Kits from Exiqon A/S Thursday, October 2, 2008 @ 7:00AM PENZBERG, Germany----Roche Diagnostics and Exiqon A/S, Vedbæk, Denmark, a provider of high-value gene expression analysis products, today announced the signing of an amendment to their 2005 license and distribution agreement for the Universal ProbeLibrary that is based on Exiqon´s proprietary Locked Nucleic Acid Oligonucleotides.
  • Police: Activists call on council for Taser controls Thursday, October 2, 2008 @ 4:38AMOutcry over whether police are using Taser stun-guns appropriately -- or whether they ought to use them at all -- continues to fuel calls for greater police transparency and accountability. Local activists are calling on the police to make changes to internal rules that govern how and when Tasers m... By Marty Levine.
  • Statins: From Fungus to Pharma Thursday, October 2, 2008 @ 3:08AMThe curiosity of biochemists, mixed with some obvious economic incentives, created a family of powerful cardiovascular drugs In 1966, Akira Endo, a young Japanese biochemist, started an adventure that would ultimately save thousands, if not millions, of lives.
  • Outlook for Medical Devices Examined in Wall street Transcript Report Wednesday, October 1, 2008 @ 1:14PM 67 WALL STREET, New York - October 1, 2008 - The Wall Street Transcript has just published its Medical Devices issue, a report offering a timely review of the sector to serious investors and industry executives. This 37-page feature contains a roundtable forum and expert industry commentary through in depth interviews with CEOs from 3 firms and 2 analysts. The full issue is available by calling ...
  • Exiqon A/S Today Announces a Grant of License to Roche Diagnostics Wednesday, October 1, 2008 @ 12:57PM -
  • OSI Pharmaceuticals Announces Conversion Period for Convertible Notes Wednesday, October 1, 2008 @ 12:52PMOSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its 2% Convertible Senior Notes due 2025 (the "notes") are now convertible at the option of the holders and will remain convertible through December 31, 2008, the last trading day of the current fiscal quarter, as provided for in the Indenture governing the notes.
  • The Scientific Business of Thomson Reuters Predicts Nobel Laureates Wednesday, October 1, 2008 @ 12:39PM one "Thomson Reuters Citation Laureates" Recognized for Their Contributions to the Advancement of Science
  • Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus ... Wednesday, October 1, 2008 @ 6:00AM Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market its Xpert MRSA/SA Blood Culture test, which runs on the GeneXpert® System, for the detection of Methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in blood culture bottles showing gram-positive cocci -- in less than one hour.
  • The Online Information Source for the Medical Device Industry Tuesday, September 30, 2008 @ 10:06AMThe underlying theme in the IVD industry during the past couple of years has been consolidation. For example, building on its previous acquisitions of Diagnostic Products Corp. and Bayer Diagnostics, Siemens Healthcare Diagnostics (Deerfield, IL) also purchased Dade Behring Inc. for $7 billion.
  • Immune System Can Hurt As Well As Help Fight Cancer, Penn Study Shows Tuesday, September 30, 2008 @ 8:09AMResearchers at the University of Pennsylvania School of Medicine have found that some proteins of the immune system can promote tumor growth. Investigators found that instead of fighting tumors, the protein C5a, which is produced during an immune response to a developing tumor, helps tumors build molecular shields against T-cell attack. These findings appeared online this week in Nature Immunolgy.
  • Identification Of Mechanism Used By Gene To Promote Metastasis In Human Cancer Cells Tuesday, September 30, 2008 @ 7:07AMVirginia Commonwealth University Institute of Molecular Medicine and VCU Massey Cancer Center researchers have discovered how a gene, melanoma differentiation associated gene-9/syntenin (mda-9/syntenin), interacts with an important signaling protein to promote metastasis in human melanoma cells, a di
  • Bradmer Announces Appointments to Board of Directors Tuesday, September 30, 2008 @ 6:00AM Bradmer Pharmaceuticals Inc. , a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced changes to its Board of Directors.
  • Scientist Plans To Test For Blood Pressure Genes Affected By Age Saturday, September 27, 2008 @ 3:06PMA geneticist at The University of Texas Health Science Center at Houston plans to scan the genomes of about 4,000 people in the hopes of finding out why blood pressure often increases as young adults age. The two-year study by principal investigator Myriam Fornage, Ph.D., is funded with a new $1.
  • RainDance Dedicates New Headquarters, Manufacturing Facility Friday, September 26, 2008 @ 2:00PM RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, today dedicated its new headquarters and operations building and unveiled its new RDT 1000 instrument.
  • OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness Thursday, September 25, 2008 @ 12:31PM( Oregon Health & Science University ) Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
  • OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness Thursday, September 25, 2008 @ 12:31PM( Oregon Health & Science University ) Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
  • Breathing During Radiation Studied By OHSU Cancer Institute Researchers Wednesday, September 24, 2008 @ 6:10PMOregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment. The results of this research were presented at the 50th annual American Society for Therapeutic Radiology and Oncology in Boston.
  • How Does The Microsatellite Alterate In Metaplasia-Dysplasia-Adenocarcinoma Sequence? Wednesday, September 24, 2008 @ 5:12PMIt is estimated that the risk of neoplasia in Barrett esophagus, through the intermediate step of dysplastic transformation of the columnar epithelium, is 125-fold higher than in the general population. But scarce data are available on genetic alterations occurring in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus.
  • Immunohistochemical Localization Of Glutathione-S-Transferase-Pi In Human Colorectal Polyps Wednesday, September 24, 2008 @ 5:11PMSpecific molecular forms of GST are known to be expressed in preneoplastic cells, and have been known to participate in their resistance to drugs. GST-pi are present in most epithelial tissues of the human gastrointestinal tract. Significant amounts of the class pi GST was expressed in the majority of human tumors and human tumor cell lines.
  • The Effect Of Curcuma Wenyujin On Human HepG2 Cancer Cells Wednesday, September 24, 2008 @ 5:10PMHepatocellular carcinoma (HCC) is the fifth most common cancer with more than 1 million fatalities occurring annually worldwide. Nowadays in China, the essential oil of Curcuma wenyujin (CWO) has been used as an injection to cure paediatric diseases such as acute upper respiratory infections, viral myocarditis and acute pneumonia.
  • 100% Results From Sequenom Wednesday, September 24, 2008 @ 2:58PMThe company presents more data on its molecular diagnostic and buys a lab to run the tests in.
  • Scientist plans to test for blood pressure genes affected by age Wednesday, September 24, 2008 @ 12:23PMA geneticist at The University of Texas Health Science Center at Houston plans to scan the genomes of about 4,000 people in the hopes of finding out why blood pressure often increases as young adults age.
  • Lance Armstrong Unveils Global Cancer Awareness Campaign and Details of His Return to Cycling Wednesday, September 24, 2008 @ 11:38AM Today, Lance Armstrong, cancer survivor, cycling champion and founder and chairman of the Lance Armstrong Foundation (LAF), announced the creation of the LIVESTRONG™ Global Cancer Awareness Campaign focused on supporting the 25 million people living with cancer worldwide, dispelling the misconceptions surrounding the disease and urging world leaders to make cancer a greater priority.
  • Research Into Deadly Cancer In Dogs May Also Have Human Applications Wednesday, September 24, 2008 @ 7:17AMA new study jointly conducted by Oregon State University College of Veterinary Medicine and the Oregon Health & Science University Cancer Institute may one day help not only our canine friends with cancer, but also people with the human form of the disease. Forging this unique relationship is OSU veterinary oncologist and researcher Stuart Helfand, D.V.M., and Brian Druker, M.D.
  • ZaBeCor Pharmaceuticals Announces Formation of Biothorpe Pharmaceuticals Wednesday, September 24, 2008 @ 7:12AM ZaBeCor Pharmaceuticals announces today the formation of its new subsidiary Biothorpe Pharmaceuticals, a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer. Recent studies in academia and in the biopharmaceutical industry indicate that Syk kinase is required for the proliferation of malignant cells in several ...
  • New Instrument Quickly Examines Multiple Proteins in a Single Cancer Sample Tuesday, September 23, 2008 @ 3:21PM Researchers have demonstrated a new instrument that makes it possible to detect and quantify multiple clinically important proteins in a single tumor sample using conventional staining.
  • Sequenom Announces Acquisition of CLIA-Certified Laboratory and Partnerships with Spectrum Health and Van Andel ... Tuesday, September 23, 2008 @ 12:30PMSequenom (NASDAQ:SQNM) today announced that it entered into an agreement to acquire the Center for Molecular Medicine (CMM), a Clinical Laboratory Improvement Act (CLIA) certified clinical diagnostics laboratory based in Grand Rapids, Michigan. CMM is an innovative joint venture between Spectrum Health, one of the largest not-for-profit health systems in Michigan, and the Van Andel Research ...
  • Sequenom Announces Acquisition of CLIA-Certified Laboratory and Partnerships with Spectrum Health and Van Andel ... Tuesday, September 23, 2008 @ 12:05PM SAN DIEGO----Sequenom today announced that it entered into an agreement to acquire the Center for Molecular Medicine , a Clinical Laboratory Improvement Act certified clinical diagnostics laboratory based in Grand Rapids, Michigan.
  • $5.4m Marsden funding boost for Massey researchers Tuesday, September 23, 2008 @ 12:17AMEleven research projects led by Massey staff have been awarded a total of $5.4m in funding over the next three years from the Marsden Fund administered by the Royal Society.
  • The Sign For Progression Of Colorectal Carcinoma Monday, September 22, 2008 @ 7:09AMThe process of tumor invasion and metastasis is associated with alterations in the functions of several adhesion molecules. In general, tumor cells lose their capacity for normal adherence, which facilitates their detachment from their site of origin. alpha-catenin links E-cadherin to the actin cytoskeleton via its association with either beta- or gamma-catenin.
  • Molecular Insight Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference Monday, September 22, 2008 @ 7:00AM CAMBRIDGE, Mass.----Molecular Insight Pharmaceuticals, Inc. announced today that David S. Barlow, Chairman and Chief Executive Officer of Molecular Insight Pharmaceuticals, will present at the upcoming UBS Global Life Sciences Conference on Wednesday, September 24, 2008.
  • Study Of Tumor Growth And Tissue Disruption Identifies Key Components In The Immune Response To Cancers Friday, September 19, 2008 @ 6:11AMKnee scrapes and tumor growth might have more in common than you think. The idea that tumor growth triggers the same immune response as a cut or wound was once a highly controversial notion. However, increasing evidence supports the idea that the same cellular mechanisms which heal a skinned knee might also have a role in preventing the growth of tumors.
  • Sequenom to Webcast Analyst and Investor Briefing Presentation on September 23 Thursday, September 18, 2008 @ 8:00AM Sequenom today announced that a live audio webcast and accompanying slide presentation will be provided for its analyst and investor briefing event "Sequenom Analyst and Investor Briefing."
  • Following Spinal Cord Injury, Sole Use Of Impaired Limb Improves Recovery Thursday, September 18, 2008 @ 6:17AMA new study finds that following minor spinal cord injury, rats that had to use impaired limbs showed full recovery due to increased growth of healthy nerve fibers and the formation of new nerve cell connections.
  • Invitrogen and Applied Biosystems Announce Divisional Structure and Executive Leadership Team Wednesday, September 17, 2008 @ 3:45PMInvitrogen Corporation (NASDAQ: IVGN) and Applied Biosystems Inc. (NYSE: ABI) today announced the divisional structure and the executive leadership team for the combination of the two companies. The new structure will become effective upon close of the proposed merger, which is conditional upon shareholder and European Commission approvals.
  • Invitrogen and Applied Biosystems Announce Divisional Structure and Executive Leadership Team Wednesday, September 17, 2008 @ 3:20PM CARLSBAD, Calif. & FOSTER CITY, Calif.----Invitrogen Corporation and Applied Biosystems Inc. today announced the divisional structure and the executive leadership team for the combination of the two companies.
  • Benchmark cyanobacterium sequenced could be cheap renewable energy source Wednesday, September 17, 2008 @ 2:23PM(PhysOrg.com) -- A team of researchers headed by biologists at Washington University in St. Louis has sequenced the genome of a unique bacterium that manages two disparate operations — photosynthesis and nitrogen fixation — in one little cell during two distinct cycles daily.
  • Genstruct Names Louis Latino VP of Sales Wednesday, September 17, 2008 @ 11:29AMCAMBRIDGE, Mass. , Sept. 17 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics and molecular diagnostics, announced today that it has appointed Louis Latino as VP of Sales.
  • Enzo Biochem to Present at UBS 2008 Global Life Sciences Conference Wednesday, September 17, 2008 @ 9:16AMEnzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, will make a presentation at the UBS 2008 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, on Tuesday, September 23, 2008, at 10:00 A.M. ...
  • SOLiD(TM) System Enables Single Cell Gene Expression Profiling to Advance Stem Cell Research Wednesday, September 17, 2008 @ 6:30AM FARMINGTON, Conn.----Today, scientists from Applied Biosystems will present data at the Connecticut Stem Cell Technology Symposium revealing how the company’s ultra-high-throughput genomic analysis platform, the SOLiD™ System, generated genome-wide expression profiling data at the single cell level.
  • Combining Old And New Therapies To Tackle Atherosclerosis Tuesday, September 16, 2008 @ 10:10AMFuturistic nanotechnology has been teamed with a decades-old drug to beat atherosclerotic plaques in research conducted at Washington University School of Medicine in St. Louis. The scientists have found that drug-laced nanoparticles plus a statin could stop the growth of tiny blood vessels that feed arterial plaques.
  • Researchers Presenting TB4 Ophthalmic Data at Military Vision Conference Tuesday, September 16, 2008 @ 7:30AM BETHESDA, Md.----REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers from Kresge Eye Institute, Wayne State University and Detroit Mercy School of Dentistry, Detroit, MI are presenting new data on Tβ4’s ability to down-regulate inflammation in the eye at the Third Biennial Military Vision Research Symposium: Traumatic Eye and Brain Injury on September 16-18, 2008 at the Schepens ...